Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 13-Feb-24 8:19 PM View:  | Newton Charles W. Chief Financial Officer | Lyell Immunopharma, Inc. (LYEL) | 09-Feb-24 | Grant | 40,000 | -- | -- | 458% 8.73K to 48.73K | |
| 13-Feb-24 8:25 PM View: | Lang Matthew Chief Business Officer | Lyell Immunopharma, Inc. (LYEL) | 09-Feb-24 | Grant | 50,000 | -- | -- | 100% 0 to 50.0K | |
| 13-Feb-24 8:22 PM View: | Lee Gary K. Chief Scientific Officer | Lyell Immunopharma, Inc. (LYEL) | 09-Feb-24 | Grant | 40,000 | -- | -- | 315% 12.7K to 52.7K | |
| 13-Feb-24 8:17 PM View: | Seely Lynn President and CEO Director | Lyell Immunopharma, Inc. (LYEL) | 09-Feb-24 | Grant | 200,000 | -- | -- | 100% 0 to 200.0K | |
| 13-Feb-24 8:24 PM View: | Hill Stephen J. Chief Operating Officer | Lyell Immunopharma, Inc. (LYEL) | 09-Feb-24 | Grant | 40,000 | -- | -- | 448% 8.93K to 48.93K | |
| 17-Aug-23 4:23 PM View: | Klausner Richard Director | Lyell Immunopharma, Inc. (LYEL) | 15-Aug-23 | Sale | 58,020 | $2.28 | $132,286.00 | (1%) 3.96M to 3.9M | |
| 27-Sep-22 6:14 PM View: | Klausner Richard Director | Lyell Immunopharma, Inc. (LYEL) | 23-Sep-22 | Market Sale | 11,100 | $6.40 | $71,041.10 | (< 1%) 3.97M to 3.96M | (3%) |
| 09-Sep-22 4:05 PM View: | Bishop Hans Edgar Director | Lyell Immunopharma, Inc. (LYEL) | 08-Sep-22 | Option Exercise | 145,380 | $0.10 | $14,538.00 | 3% 4.54M to 4.69M | |
| 25-Feb-22 4:05 PM View: | Bishop Hans Edgar Director | Lyell Immunopharma, Inc. (LYEL) | 23-Feb-22 | Option Exercise | 993,428 | $0.10 | $99,342.80 | 28% 3.55M to 4.54M | |
| 14-Dec-21 4:57 PM View: | Friedman Cathy Director | Lyell Immunopharma, Inc. (LYEL) | 14-Dec-21 | Disposition (other) | 3,765,840 | -- | -- | (92%) 4.1M to 336.37K | |
| 14-Dec-21 4:57 PM View: | Friedman Cathy Director | Lyell Immunopharma, Inc. (LYEL) | 14-Dec-21 | Acquisition (other) | 218,722 | -- | -- | 6% 3.88M to 4.1M | |
| 23-Jun-21 5:36 PM View: | Klausner Richard Executive Chairman Director | Lyell Immunopharma, Inc. (LYEL) | 21-Jun-21 | Conversion Duplicate | 3,765,840 | -- | -- | 127% 2.97M to 6.73M | |
| 23-Jun-21 6:14 PM View: | Glaxosmithkline Plc 10% Owner | Lyell Immunopharma, Inc. (LYEL) | 21-Jun-21 | Conversion | 30,253,200 | -- | -- | 100% 0 to 30.25M | |
| 23-Jun-21 5:33 PM View: | Friedman Cathy Director | Lyell Immunopharma, Inc. (LYEL) | 21-Jun-21 | Conversion | 3,765,840 | -- | -- | 3766% 100.0K to 3.87M | |
| 23-Jun-21 5:38 PM View: | Nelsen Robert Director 10% Owner | Lyell Immunopharma, Inc. (LYEL) | 21-Jun-21 | Conversion | 36,412,700 | -- | -- | 100% 0 to 36.41M | |
| 23-Jun-21 5:33 PM View: | Friedman Cathy Director | Lyell Immunopharma, Inc. (LYEL) | 21-Jun-21 | Market Purchase | 17,648 | $17.00 | $300,016.00 | < 1% 3.87M to 3.88M | |
| 23-Jun-21 5:35 PM View: | Bishop Hans Edgar Director | Lyell Immunopharma, Inc. (LYEL) | 21-Jun-21 | Conversion | 546,806 | -- | -- | 18% 3.0M to 3.55M | |
| 23-Jun-21 5:42 PM View: | Arch Venture Partners Ix, LLC 10% Owner | Lyell Immunopharma, Inc. (LYEL) | 21-Jun-21 | Conversion Duplicate | 36,412,700 | -- | -- | 100% 0 to 36.41M |
